Venous thromboembolism in cancer patients: Expanding horizons

Seminars in Thrombosis and Hemostasis

Volumn 28, Issue SUPPL. 3, 2002, Pages 19-23

  Bergqvist, David ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cancer; Low molecular weight heparin; Surgery; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; ANTINEOPLASTIC AGENT; FIBRINOLYTIC AGENT; WARFARIN;

BLEEDING; CANCER PATIENT; CANCER SCREENING; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HEMOSTASIS; HUMAN; INCIDENCE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; THROMBOEMBOLISM; VEIN THROMBOSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; META ANALYSIS; MULTICENTER STUDY; NEOPLASM; PARANEOPLASTIC SYNDROME; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK; THROMBOPHILIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; META-ANALYSIS; MULTICENTER STUDIES; NEOPLASMS; PARANEOPLASTIC SYNDROMES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 0036351560     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34071     Document Type: Conference Paper

References (17)

1. Phlegmasia alba dolens
2. Deep venous thrombosis and occult malignancy: An epidemiological study
3. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
4. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations
5. Prevention of venous thromboembolism
6. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison
7. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
8. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients
9. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
10. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®)
11. Risk of deep-vein thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
12. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study
13. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. A double-blind, randomized comparison
14. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer
15. Venous thromboembolism and cancer: A two-way clinical association
16. Canthanox, a randomised controlled study comparing low-molecular-weight heparin and warfarin for the prevention of recurrent venous thromboembolism in patients with cancer
17. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency